StockDriftsStockDriftsUbiologics (206650) has 33 disclosed insider purchases and 2 disclosed disposals on record, filed by 6 distinct insiders. Together those filings cover ₩10.1B ($7.0M) in reported transaction value. The earliest filing StockDrifts holds for Ubiologics is dated 2023-09-20; the most recent is 2026-07-06. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +6.64%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-07-06 | BUY | Market Buy | 허태영 Taeyoung Heo | CEO | 2.0K | ₩8,510 | -5.9% | ₩17M ($12K) |
| 2026-07-03 | BUY | Market Buy | 허태영 Taeyoung Heo | CEO | 1.0K | ₩8,710 | -8.0% | ₩9M ($6K) |
| 2026-07-02 | BUY | Market Buy | 허태영 Taeyoung Heo | CEO | 6.0K | ₩8,600 | -6.9% | ₩52M ($36K) |
| 2026-04-28 | SELL | Market Sell | 신영희 Younghee Shin | Managing Director | -685 | ₩13,320 | +3.9% | ₩9M ($6K) |
| 2026-04-21 | BUY | Market Buy | 신영희 Younghee Shin | Managing Director | 685 | ₩13,470 | -5.0% | ₩9M ($6K) |
| 2026-04-06 | BUY | Market Buy | 바이오노트 bionote | - | 29.6K | ₩13,320 | +1.1% | ₩395M ($274K) |
| 2026-04-02 | BUY | Market Buy | 바이오노트 bionote | - | 60.0K | ₩13,330 | +1.1% | ₩800M ($555K) |
| 2026-04-01 | BUY | 신규선임 | 김락기 Kim Rak-gi | moving | 3.4K | ₩14,030 | -4.0% | ₩47M ($33K) |
| 2026-03-30 | BUY | Market Buy | 바이오노트 bionote | - | 20.0K | ₩13,750 | -2.0% | ₩275M ($191K) |
| 2026-03-25 | BUY | Market Buy | 바이오노트 bionote | - | 115.6K | ₩14,070 | -4.3% | ₩1.6B ($1.1M) |
| 2026-03-24 | BUY | Market Buy | 바이오노트 bionote | - | 25.0K | ₩13,990 | -3.7% | ₩350M ($243K) |
| 2026-03-23 | BUY | Market Buy | 바이오노트 bionote | - | 15.0K | ₩13,970 | -3.6% | ₩210M ($146K) |
| 2026-03-20 | BUY | Market Buy | 바이오노트 bionote | - | 10.5K | ₩14,120 | -4.6% | ₩148M ($103K) |
| 2026-03-18 | BUY | Market Buy | 바이오노트 bionote | - | 19.4K | - | - | - |
| 2026-03-16 | BUY | Market Buy | 바이오노트 bionote | - | 10.0K | - | - | - |
| 2026-03-13 | BUY | Market Buy | 바이오노트 bionote | - | 10.0K | - | - | - |
| 2026-03-12 | BUY | Market Buy | 바이오노트 bionote | - | 14.0K | - | - | - |
| 2026-03-11 | BUY | Market Buy | 바이오노트 bionote | - | 20.8K | - | - | - |
| 2026-01-28 | BUY | 주식매수선택권 | 신정섭 Shin Jeong-seop | Managing Director | 10.0K | ₩11,870 | +19.3% | ₩119M ($82K) |
| 2026-01-28 | BUY | 주식매수선택권 | 장재선 Jang Jae-seon | moving | 5.0K | ₩11,870 | +19.3% | ₩59M ($41K) |
| 2026-01-28 | BUY | 주식매수선택권 | 전동운 Jeon Dong-woon | Managing Director | 10.0K | ₩11,870 | +19.3% | ₩119M ($82K) |
| 2026-01-02 | BUY | Market Buy | 백영옥 Baek Young-ok | CEO | 10.0K | ₩11,410 | +24.1% | ₩114M ($79K) |
| 2025-11-27 | BUY | 주식매수선택권 | 태영진 Taeyoungjin | moving | 25.0K | ₩12,470 | +13.6% | ₩312M ($216K) |
| 2025-10-15 | BUY | 주식매수선택권 | 전동운 Jeon Dong-woon | Managing Director | 10.0K | ₩12,850 | +10.2% | ₩129M ($89K) |
| 2025-10-15 | BUY | 주식매수선택권 | 신정섭 Shin Jeong-seop | Managing Director | 2.0K | ₩12,850 | +10.2% | ₩26M ($18K) |
| 2025-04-03 | BUY | 주식매수선택권 | 신정섭 Shin Jeong-seop | Managing Director | 10.0K | ₩10,830 | +30.8% | ₩108M ($75K) |
| 2025-04-03 | BUY | 주식매수선택권 | 최영진 Youngjin Choi | Managing Director | 5.0K | ₩10,830 | +30.8% | ₩54M ($38K) |
| 2025-04-03 | BUY | 주식매수선택권 | 장재선 Jang Jae-seon | moving | 15.0K | ₩10,830 | +30.8% | ₩162M ($113K) |
| 2024-08-20 | BUY | 주식매수선택권 | 전동운 Jeon Dong-woon | moving | 5.0K | ₩11,930 | +18.7% | ₩60M ($41K) |
| 2024-08-20 | SELL | Market Sell | 채수민 Chae Su-min | moving | -10.0K | ₩11,930 | -18.7% | ₩119M ($83K) |
| 2024-08-20 | BUY | 주식매수선택권 | 채수민 Chae Su-min | moving | 19.0K | ₩11,930 | +18.7% | ₩227M ($157K) |
| 2024-05-29 | BUY | Market Buy | 바이오노트 bionote | - | 2.2K | ₩12,700 | +11.5% | ₩28M ($19K) |
| 2024-05-28 | BUY | Market Buy | 바이오노트 bionote | - | 14.8K | ₩12,360 | +14.6% | ₩183M ($127K) |
| 2024-05-24 | BUY | Market Buy | 바이오노트 bionote | - | 19.0K | ₩12,180 | +16.3% | ₩231M ($161K) |
| 2024-04-15 | BUY | Market Buy | 바이오노트 bionote | - | 53.4K | ₩13,900 | +1.9% | ₩742M ($515K) |
| 2024-04-12 | BUY | Market Buy | 바이오노트 bionote | - | 51.7K | ₩12,070 | +17.3% | ₩624M ($433K) |
| 2024-04-12 | BUY | Market Buy | 바이오노트 bionote | - | 15.5K | ₩12,070 | +17.3% | ₩187M ($130K) |
| 2024-04-11 | BUY | Market Buy | 바이오노트 bionote | - | 86.8K | ₩12,000 | +18.0% | ₩1.0B ($723K) |
| 2024-04-11 | BUY | Market Buy | 바이오노트 bionote | - | 8.5K | ₩12,000 | +18.0% | ₩102M ($71K) |
| 2024-04-09 | BUY | Market Buy | 바이오노트 bionote | - | 33.8K | ₩12,400 | +14.2% | ₩419M ($291K) |
| 2024-04-08 | BUY | Market Buy | 바이오노트 bionote | - | 55.8K | ₩11,980 | +18.2% | ₩669M ($465K) |
| 2024-04-05 | BUY | Market Buy | 바이오노트 bionote | - | 1.4K | ₩12,120 | +16.8% | ₩16M ($11K) |
| 2024-04-05 | SELL | 증여 | 박영신 Youngshin Park | Managing Director | -39.0K | ₩12,120 | -16.8% | ₩473M ($328K) |
| 2024-04-04 | BUY | Market Buy | 바이오노트 bionote | - | 77.8K | ₩12,030 | +17.7% | ₩936M ($650K) |
| 2024-04-04 | BUY | 주식매수청구권 행사 | 신정섭 Shin Jeong-seop | Managing Director | 6.0K | ₩12,030 | +17.7% | ₩72M ($50K) |
| 2024-03-26 | BUY | 신규선임 | 허태영 Taeyoung Heo | CEO | 2.0K | ₩12,500 | +13.3% | ₩25M ($17K) |
| 2024-03-22 | BUY | Market Buy | 바이오노트 bionote | - | 5.5K | ₩12,770 | +10.9% | ₩71M ($49K) |
| 2024-03-07 | BUY | Market Buy | 바이오노트 bionote | - | 46.0K | ₩12,590 | +12.5% | ₩580M ($403K) |
| 2024-03-06 | BUY | Market Buy | 바이오노트 bionote | - | 13.7K | ₩12,700 | +11.5% | ₩174M ($121K) |
| 2023-09-20 | BUY | Market Buy | 최영진 Youngjin Choi | Managing Director | 100 | ₩12,300 | +15.1% | ₩1M ($854) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Ubiologics. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.